New food solutions for cancer patients: a consumer-centred approach
SHARES
The Oncofood project revealed some expectations of cancer patients regarding new food solutions.
Cancer is among the leading causes of death worldwide. According to the Global Cancer Observatory, in 2018 there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide.
1
One of the main challenges for cancer patients undergoing treatment is preventing or mitigating malnutrition. Cancer-related malnutrition is highly prevalent in patients undergoing cancer treatment, varying from eight to 84 percent, dependent on cancer site and stage.
2 However, not all patients suffer from malnutrition, but most experience a reduction in their daily food intake as they often have adverse side effects (eg, taste loss, bad taste in mouth, metallic taste, sores in mouth, vomiting, loss of appetite and dysphagia).
Desarrollan en Euskadi un test para detectar anticuerpos contra el coronavirus
deia.eus - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from deia.eus Daily Mail and Mail on Sunday newspapers.
Novel computer-guided design tool helps increase the efficiency of cell conversions
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: The collaborative team successfully used their computer-guided design tool IRENE to reconstruct the gene regulatory network controlling the identity of induced pluripotent stem cells (iPSCs). view more
Credit: Wyss Institute at Harvard University
(BOSTON) There is a great need to generate various types of cells for use in new therapies to replace tissues that are lost due to disease or injuries, or for studies outside the human body to improve our understanding of how organs and tissues function in health and disease. Many of these efforts start with human induced pluripotent stem cells (iPSCs) that, in theory, have the capacity to differentiate into virtually any cell type in the right culture conditions. The 2012 Nobel Prize awarded to Shinya Yamanaka recognized his discovery of a strategy that can reprogram adult cells to become iPSCs by providing them with a defined set of gene-regulatory transcription factors (TFs). However, progressing from there